Center on Health Equity & Access

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.

Debra Patt, MD, PhD, MBA, MPH, spoke at SABCS about the importance of patient-investigator collaboration to enhance the clinical trial process.

Financial and social barriers hinder access to specialized care and impact treatment outcomes for adolescents and young adults with leukemia.

Early fertility counseling is necessary for young patients before treatment limits options, said Yara Abdou, MD, of the University of North Carolina at Chapel Hill.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

Many US patients with diabetes cannot afford their medical care. The authors review the impact of interventions that reduced and/or eliminated diabetes-related costs.

Research at the San Antonio Breast Cancer Conference highlights T-DXd's superior efficacy and safety in HER2+ metastatic breast cancer, especially among diverse populations.

Democrats move to extend ACA subsidies as enrollment closes, leaving consumers uncertain about premiums, coverage, and alternative health options.

The RAISE program provides awareness and shares comprehensive solutions to address the multifaceted reasons for missing and incomplete data across the real-world data continuum.

While DTC pharmacy models offer convenience, they may create cost, access, and guidance barriers for the "working poor."

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

ICHRAs may help employers and employees manage rising premiums and the loss of extended tax credits, according to expert insights from Ben Light.

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

Public health dental hygienists expand dental care access and oral health education in underserved communities, improving overall health outcomes.

Hereditary ovarian cancer genes occur across diverse populations, supporting inclusive genetic testing.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.